Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Colorectal Cancer

Join Kalpana Devaraj, MD and Wells Messersmith, MD from University of Colorado Cancer Center as they present their expertise on a range of cases pertaining to colorectal cancer.

The management of metastatic colorectal cancer (mCRC) involves a continuum of care in which patients are exposed sequentially to a variety of active agents, either in combinations or as monotherapies. A new agent, which represents an additional line of therapy, was added to the 2016 version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) with NCCN Evidence Blocks™ for Colon and Rectal Cancers. Trifluridine/tipiracil (TAS-102) improved OS in the randomized phase III RECOURSE study compared with placebo (7.1 months vs 5.3 months; HR, 0.68; P<.001) in patients who were refractory to at least 2 prior standard regimens containing a fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab, and, if KRAS and NRAS wild-type, cetuximab or panitumumab. Trifluridine/tipiracil can be given before or after regorafenib, after all other standard therapies have been given; no data inform the best order of these final lines of therapies.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Assess data on the risks and benefits of new and emerging treatment options to individualize managment for patients with metastatic colorectal cancer.
  • Evaluate the molecular testing that should be performed for patients with metastatic colorectal cancer and the possible impact of test results on treatment decisions.
  • Discuss the rationale behind recent updates to the NCCN Guidelines for Colon Cancer and the NCCN Guidelines for Rectal Cancer.
Additional information
Supporters: 

This educational activity is supported by educational grants from Astellas; AstraZeneca; Bayer Healthcare Pharmaceuticals Inc.; Celgene Corporation; Eisai; Genomic Health, Inc.; Janssen Biotech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Sanofi-Genzyme; and Takeda Oncology. This activity is supported by educational funding provided by Amgen. This activity is supported by an independent medical education grant from Bristol-Myers Squibb. This educational activity is supported by an unrestricted education grant from Exelixis, Inc. This educational activity is supported by an independent educational grant from Merck.

Course summary
Available credit: 
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.82 ANCC contact hours
  • 0.75 Participation
Course opens: 
09/14/2016
Course expires: 
09/14/2017
Cost:
$0.00
Part of: 
Archived Monthly Oncology Tumor Boards (July 2016 - June 2017)

Kalpana Devaraj, MD
University of Colorado Cancer Center

Wells Messersmith, MD
University of Colorado Cancer Center

 

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty listed below has no relevant financial relationships to disclose:

Kalpana Devaraj, MD, MPH

The faculty listed below have disclosed the following relevant financial relationships:

Wells Messersmith, MD
Bayer HealthCare: Grant/Research Support
Genentech, Inc.: Grant/Research Support
Immunomedics, Inc.: Grant/Research Support; Honoraria; Consulting Fees
Millennium Pharmaceuticals, Inc.: Grant/Research Support
NCI/CTEP: Grant/Research Support
OncoMed: Grant/Research Support
Pfizer Inc.: Grant/Research Support
Roche/Genentech: Grant/Research Support

NCCN Staff Disclosures

The activity planning staff listed below has no relevant financial relationships to disclose:

Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Jennifer McCann Weckesser

The NCCN clinical information team listed below, who have reviewed content, has no relevant financial relationships to disclose:

Deborah Freedman-Cass, PhD

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

National Comprehensive Cancer Network designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 0.82 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.

Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Type of Activity: Knowledge

National Comprehensive Cancer Network designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of continuing education credit in states that recognize ACPE accredited providers.

Universal Activity Number: 0836-0000-16-104-H01-P

Available Credit

  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.82 ANCC contact hours
  • 0.75 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing